In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells
Abstract
In addition to long-term self-renewal capability, human mesenchymal stem cells (MSCs) possess versatile differentiation potential ranging from mesenchyme-related multipotency to neuroectodermal and endodermal competency. Of particular concern is hepatogenic potential that can be used for liver-directed stem cell therapy and transplantation. In this study, we have investigated whether human umbilical cord blood (UCB)-derived MSCs are also able to differentiate into hepatocyte-like cells. MSCs isolated from UCB were cultured under the pro-hepatogenic condition similar to that for bone marrow (BM)-derived MSCs. Expression of a variety of hepatic lineage markers was analyzed by flow cytometry, RT-PCR, Western blot, and immunofluorescence. The functionality of differentiated cells was assessed by their ability to incorporate DiI-acetylated low-density lipoprotein (DiI-Ac-LDL). As the cells were morphologically transformed into hepatocyte-like cells, they expressed Thy-1, c-Kit, and Flt-3 at the cell surface, as well as albumin, alpha-fetoprotein, and cytokeratin-18 and 19 in the interior. Moreover, about a half of the cells were found to acquire the capability to transport DiI-Ac-LDL. Based on these observations, and taking into account immense advantages of UCB over other stem cell sources, we conclude that UCB-derived MSCs retain hepatogenic potential suitable for cell therapy and transplantation against intractable liver diseases.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MSCs derived from various sources can differentiate into functional HLCs along the endodermal lineage under both in vitro and in vivo conditions in experimental animal models and humans.
“It has been reported in experimental animal models and humans that MSCs derived from various sources can differentiate into functional HLCs along the endodermal lineage under both in vitro and in vivo conditions [90–92].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [91]
Allogeneic UC-MSCs have many advantages over BM-MSCs and AD-MSCs, including wide availability, ethical considerations, safety (lower risk of viral transmission and less pronounced immune response), and superior characteristics (more primitive and higher proliferative capacity).
“Allogeneic UC-MSCs have many advantages over BM-MSCs and AD-MSCs, including 1) wide availability, as they can be obtained from the discarded UC, enabling large-scale production without donor attrition; 2) ethical considerations, as they are easier and less invasive extraction processes with no ethical concerns; 3) safety, as they carry a lower risk of viral transmission and elicit a less pronounce”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [91]
The citation lists haven’t been fetched yet
References 52 · Cited by 248
- Authors
- Hong, S. H., Gang, E. J., Jeong, J. A., Ahn, C., Hwang, S. H., Yang, I. H., Park, H. K., Han, H., & Kim, H.
- Affiliations
- Hanyang University (KR)
- Corresponding author
- Kim, Hoeon
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 330
- Issue
- 4
- Pages
- 1153-1161
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2024922183
- Cited by
- 248
- References
- 52
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 3 · 2022: 8 · 2021: 5 · 2020: 8 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 14 · 2015: 12 · 2014: 9 · 2013: 19 · 2012: 27
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical and Biophysical Research Communications (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- mesenchymal stem cells, umbilical cord blood, hepatocyte-like cells, hepatocyte differentiation, liver regeneration, stem cell therapy, liver transplantation, albumin, alpha-fetoprotein, cytokeratin, LDL uptake, CD90, CD117, FLT3
- MeSH terms
- Acetylation, Cell Differentiation, Cells, Cultured, Fetal Blood, Flow Cytometry, Humans, Lipoproteins, LDL, Biomarkers, Reverse Transcriptase Polymerase Chain Reaction, Hepatocytes, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review